In the context of metabolic diseases, most studies have reported elevated circulating levels of visfatin/Nampt in different clinical conditions, such as obesity, type 2 diabetes mellitus, and the metabolic syndrome which represent independent risk factors for inflammation-related atherothrombotic diseases [28, 29]. Here, NAMPT is linked to obesity disorder.